CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a targeted and non-destructive treatment for atrial fibrillation (AF) using chemogenetics. By utilizing genetically modified cells, the treatment seeks to modulate cardiac electrical properties without pain or side effects, potentially preventing further AF episodes.
Atrial fibrillation (AF) is the most common sustained arrhythmia and is responsible for significant morbidity, mortality, and burden on the health care systems.
Importantly, AF events may promote further fibrillatory episodes by inducing atrial remodelling.
Traditional therapies for AF have relatively limited efficacy, and are either destructive (ablation), painful (defibrillation), or associated with side effects because of their global cardiac and systemic actions (drugs).
Consequentially, nov…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
